Ethan B. Ludmir, MD, shares the rationale for and the outcomes derived from the EXTEND trial in oligometastatic pancreatic ductal adenocarcinoma.
Ethan B. Ludmir, MD,
Advertisement
Articles by Ethan B. Ludmir, MD,
Advertisement
Latest Updated Articles
Dr Ludmir on the Rationale For the EXTEND Trial in PDACPublished: January 20th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5